CERTIFICATION

I, PHILIP DRACHMAN, CERTIFY THE FOLLOWING:

1.    I have reviewed this quarterly report on Form 10-QSB of Amazon Biotech,
      Inc.;

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report;

3.    Based on my knowledge, the financial statements, and other financial
      information included in this quarterly report, fairly present in all
      material respects the financial condition, results of operations and cash
      flows of Amazon Biotech, Inc. as of, and for, the periods presented in
      this quarterly report;

4.    Amazon Biotech, Inc.'s other certifying officer and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-14 and 15d-14) for Amazon Biotech, Inc.
      and we have done the following:

      a.    designed such disclosure controls and procedures to ensure that
            material information relating to Amazon Biotech, Inc. is made known
            to us by others within the Company, particularly during the period
            in which this quarterly report is being prepared;

      b.    evaluated the effectiveness of Amazon Biotech, Inc.'s disclosure
            controls and procedures as of a date within 90 days prior to the
            filing date of this quarterly report (the "Evaluation Date"); and

      c.    presented in this quarterly report our conclusions about the
            effectiveness of the disclosure controls and procedures based on our
            evaluation as of the Evaluation Date;

5.    Amazon Biotech, Inc.'s other certifying officer and I have disclosed,
      based on our most recent evaluation, to Amazon Biotech, Inc.'s auditors
      and the audit committee of Amazon Biotech Inc.'s board of directors:

      a.    all significant deficiencies in the design or operation of internal
            controls which could adversely affect Amazon Biotech, Inc.'s ability
            to record, process, summarize and report financial data and have
            identified for Amazon Biotech, Inc.'s auditors any material
            weaknesses in internal controls; and

      b.    any fraud, whether or not material, that involves management or
            other employees who have a significant role in Amazon Biotech,
            Inc.'s internal controls; and

6.    Amazon Biotech, Inc.'s other certifying officer and I have indicated in
      this quarterly report whether or not there were significant changes in
      internal controls or in other factors that could significantly affect
      internal controls subsequent to the date of our most recent evaluation,
      including any corrective actions with regard to significant deficiencies
      and material weaknesses.


June 17, 2004                    /s/ Philip Drachman
                                ------------------------------------------------
                                Philip Drachman
                                President
                                (Principal Financial Officer)